Medical cannabis is still prescribed around an invisible axis: CB1 receptor capacity. This vision explores a future where CB1 availability is visible as a simple percentage on your phone, guiding dosing, tolerance, safety, and a new era of ECS medicine.
2025 in ECS Research: The Year the Substrate-Driven ECS Model Came of Age
Endocannabinoid system substrate—specifically membrane fatty acid composition—is the primary determinant of CB1 receptor function, not genetics or receptor density. For years, I’ve been making the case that endocannabinoid system function is not primarily about receptor density or genetic variants, it’s about substrate availability. The composition of fatty acids in cell…
JAMA, Medical Cannabis and the Endocannabinoid Blind Spot
There is a saying in science: Absence of evidence is not evidence of absence. But in the case of the recent JAMA review on the therapeutic use of cannabis, I would propose a correction: Absence of mechanistic insight leads to the illusion of insufficient evidence. A new medical cannabis review published this…
ECS and Exercise: The Invisible Architecture of Fitness
The body keeps secrets in its blood. On a Tuesday morning in late 2024, 491 men and women stepped onto treadmills and cycle ergometers across several research institutions. None of them knew they were about to reveal something profound about the mechanics of human fitness. They simply pushed themselves toward…
When Percentages Lie: Rethinking Omega‑6 (LA & AA) Risk Biomarkers and Endocannabinoid Substrates
The blind spot in fatty acid epidemiology Since the 1960s, most circulating fatty acid data have been reported as “percent of total” rather than as absolute concentrations, because gas chromatography methods naturally produce compositional peak areas that are easy to turn into percentages (Sergeant et al., 2016; Lagerstedt et al.,…
The Swedish Sin: When Evidence-Based Medicine Meets Bureaucratic Barriers
Sweden claims to have medical cannabis. We tell patients it’s legal. But TLV threatens to make it financially inaccessible (60,000 vs 2,900 SEK/year), regions threaten to fire doctors who prescribe it, and medical schools don’t teach the biology. How bureaucratic ignorance kills a medical intervention without ever banning it.
How Diet and Exercise Modulate the Endocannabinoid System
New Evidence for the Substrate-Driven Model I came across a fascinating recent study this week in Nutritional Neuroscience that really validates something I’ve been thinking about for a while. Lima and colleagues just published research showing how diet and exercise reshape the endocannabinoid system in the brain. It all fits beautifully with what I call the substrate-driven model of ECS function. Let me walk you through what they found and why it matters. The Study: Diet, Exercise & Brain ECS The team took young rats and divided them into groups. Some got standard lab chow, others got a “palatable diet” (think: high in omega-6 fats and sugar, like a Western diet). Some rats didtreadmill training for eight weeks, others didn’t. Then they looked at CB1 receptors and NAPE-PLD enzyme levels in three key brain areas: • Hypothalamus – your energy regulation center • Frontal cortex – handles reward and decision-making…
Lipidomic Markers Predict Autism Through ECS Dysfunction
Autism research has long struggled with a fundamental question: why do so many disparate findings (maternal nutrition, inflammation, mitochondrial dysfunction, environmental exposures) all seem to correlate with ASD risk? A new systematic review may have inadvertently provided the unifying answer, though the authors themselves haven’t yet connected the dots. A…
The Biochemical Plateau: Rethinking Linoleic Acid and Heart Health
The Linoleic Acid Paradox: Protection or Peril? For decades, linoleic acid has enjoyed a privileged place in nutritional policy. It is the cornerstone of “heart-healthy” messaging, the molecular mascot of seed oils, and the quiet passenger in countless processed foods. But beneath this reputation lies a paradox: the very molecule…
The Enzyme Inhibitor Paradox: Why Anti-Obesity Drugs Keep Failing
A new study just proved something remarkable: researchers found a way to slash insulin levels by 53% in just two hours. Food intake dropped 23%. Body weight fell within 24 hours. The pharmaceutical industry should be celebrating. Except there’s a problem. By day seven, it stopped working. Completely. The mice…
